4//SEC Filing
Smith Brendan 4
Accession 0001209191-22-053498
CIK 0001674416other
Filed
Oct 11, 8:00 PM ET
Accepted
Oct 12, 5:42 PM ET
Size
5.3 KB
Accession
0001209191-22-053498
Insider Transaction Report
Form 4
Smith Brendan
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-10-07+14,000→ 14,000 totalExercise: $61.65Exp: 2032-10-07→ Common Shares (14,000 underlying)
Footnotes (1)
- [F1]This option was granted on October 7, 2022 with respect to 14,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 7, 2022.
Documents
Issuer
CRISPR Therapeutics AG
CIK 0001674416
Entity typeother
Related Parties
1- filerCIK 0001857492
Filing Metadata
- Form type
- 4
- Filed
- Oct 11, 8:00 PM ET
- Accepted
- Oct 12, 5:42 PM ET
- Size
- 5.3 KB